

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: **2013-06-10** | Period of Report: **2013-06-06**  
SEC Accession No. [0001193125-13-253483](#)

([HTML Version](#) on [secdatabase.com](#))

FILER

**IDENIX PHARMACEUTICALS INC**

CIK: [1093649](#) | IRS No.: **450478605** | State of Incorporation: **DE** | Fiscal Year End: **1231**  
Type: **8-K** | Act: **34** | File No.: [000-49839](#) | Film No.: **13903936**  
SIC: **2834** Pharmaceutical preparations

Mailing Address  
*320 BENT STREET  
CAMBRIDGE MA 02141*

Business Address  
*320 BENT STREET  
CAMBRIDGE MA 02141  
617-995-9800*

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of The Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): June 6, 2013**

---

**IDENIX PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation or organization)

**000-49839**  
(Commission  
File Number)

**45-0478605**  
(I.R.S. Employer  
Identification No.)

**320 Bent Street  
Cambridge, MA**  
(Address of principal executive offices)

**02141**  
(Zip Code)

**(617) 995-9800**

(Registrant's telephone number, including area code)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

---

**Item 5.07 Submission of Matters to a Vote of Security Holders**

Idenix Pharmaceuticals, Inc. (the “Company”) held its annual meeting of stockholders on June 6, 2013. At the annual meeting, the stockholders elected all seven of the nominees of the Company’s Board of Directors for a term of one year and until his or her successor is duly elected and qualified. In addition, at the annual meeting, the stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the current fiscal year ending December 31, 2013.

The final voting results are set forth below:

a) The seven nominees for director were elected as follows:

Nominee	For	Withheld	Non-Votes
Wayne T. Hockmeyer, Ph.D.	85,880,263	24,594,326	10,081,641
Thomas R. Hodgson	87,850,421	22,624,168	10,081,641
Tamar D. Howson	85,831,512	24,643,077	10,081,641
Denise Pollard-Knight, Ph.D.	85,273,480	25,201,109	10,081,641
Ronald C. Renaud, Jr.	87,851,315	22,623,274	10,081,641
Anthony Rosenberg	88,041,948	22,432,641	10,081,641
Michael S. Wyzga	87,849,065	22,625,524	10,081,641

b) The ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm the current fiscal year ending December 31, 2013 was approved as follows:

For: 120,197,244  
Against: 216,212  
Abstain: 142,774

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed by the undersigned hereunto duly authorized.

IDENIX PHARMACEUTICALS, INC.

Date: June 10, 2013

By: /s/Maria Stahl

Maria Stahl

Senior Vice President and General Counsel